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Objective
To assess effectiveness of the influenza vaccine among US military
dependents and US-Mexico Border populations during the 2011-12
influenza season.
Introduction
As a result of antigenic drift of the influenza viruses, the compo-
sition of the influenza vaccine is updated yearly to match circulating
strains. Consequently, there is need to assess the effectiveness of the
influenza vaccine (VE) on a yearly basis. Ongoing febrile respiratory
illness (FRI) surveillance captures data and specimens that are lever-
aged to estimate influenza VE on an annual basis.
Methods
Data from ongoing FRI surveillance at US Military and US-Mex-
ico border clinics were used to estimate VE. We conducted a case–
control study between weeks 3 and 17 of the 2011-12 influenza
season. Specimens were collected from individuals meeting FRI case
definition (fever ! 100.0 F with either cough or sore throat). Cases
were laboratory confirmed influenza infection and controls were neg-
ative for influenza. Interviewer-administered questionnaires collected
information on patient demographics and clinical factors and vacci-
nation status. Logistic regression was used to calculate the crude and
adjusted odds ratios (OR) and VE was computed as (1-OR) x 100%.
Vaccine protection was assumed to begin 14 days post-vaccination.
Results
A total of 155 influenza positive cases and 429 influenza negative
controls were included in the analysis - 72 cases were influenza
A(H3N2), 38 cases were influenza A(H1N1), and 45 cases were in-
fluenza B. Overall adjusted VE against laboratory-confirmed in-
fluenza was 46% (95% CI, 19–64%); unadjusted was 39% (95% CI,
11–58%). Influenza subtype analyses revealed moderate protection
against A/H3 and A/H1 and lower protection against B. Lowest esti-
mated VE was seen in older individuals, age 65 and older.
Conclusions
Influenza vaccination was moderately protective against labora-
tory confirmed influenza in this population. Continued surveillance
is important in monitoring the effectiveness of the influenza vaccine.
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